Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

Ammar Sukari,Misako Nagasaka,Roba Alhasan,Dhaval Patel,Antoinette J Wozniak,Radhakrishnan Ramchandren,Ulka N. Vaishampayan,Amy Weise,Lawrence E. Flaherty,Hyejeong Jang,Seongho Kim,Shirish M. Gadgeel

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution

2019

Ammar Sukari
Misako Nagasaka
Roba Alhasan
Dhaval Patel
Antoinette J Wozniak
Radhakrishnan Ramchandren
Ulka N. Vaishampayan
Amy Weise
Lawrence E. Flaherty
Hyejeong Jang
Seongho Kim
Shirish M. Gadgeel

Background Data on the characteristics of patients who are likely to experience adverse events, both immune-related and non-immune-related, from programmed cell death-1 (PD1) inhibitors are limited.

Keywords:

Cancer research
Oncology
Cancer
Immune checkpoint
Biology
Internal medicine
Adverse effect
Nephrectomy
Renal cell carcinoma
Head and neck squamous-cell carcinoma
Metastasis
Common Terminology Criteria for Adverse Events
Primary tumor
Pneumonitis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations